Search PubMedSearch

SEARCH · Search PubMed

Results for “Minichromosome formation”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

3 recordsLinked to original sources

Structural genome variation drives adaptation of the xylose-fermenting yeast Scheffersomyces stipitis to lignocellulosic hydrolysates.

Second-generation (2G) bioethanol from lignocellulosic feedstocks is a sustainable alternative to fossil fuels. However, its production is constrained by the poor performance of industrial microbes in hydrolysates that are generated during biomass pretreatment. Scheffersomyces stipitis is a native xylose fermenting yeast and a promising platform for 2G bioethanol production, and adaptive evolution under hydrolysate stress has yielded strains with enhanced performance. However, the chromosomal basis of this adaptation is unknown. Here, we demonstrate that chromosome scale structural variation, rather than point mutations, underlies the improved phenotype of the evolved strains. By integrating long- and short-read genome sequencing, we identify two major chromosomal rearrangements in the top performing isolate: a reciprocal translocation between chromosomes 1 and 2 that disrupts the NUDIX hydrolase gene YSA1, and the formation of a mitotically stable 175 kb minichromosome derived from chromosome 5. Functional analyses show that disruption of YSA1 enhances xylose utilisation and ethanol yield, while the minichromosome contributes to improved performance in hydrolysate conditions. These findings provide direct evidence that balanced rearrangements and minichromosome formation can be selected during prolonged stress and can generate adaptive phenotypes. Taken together, our study establishes genome reorganisation as a key driver of adaptation in S. stipitis.

Xylose

MCM8 promotes colorectal cancer progression by competitively inhibiting HRD1-mediated CDC42 ubiquitination and degradation.

BACKGROUND: Colorectal cancer (CRC) ranks among the top three in both incidence and mortality rates of malignant tumors worldwide. For patients with advanced colon cancer, radical surgery is challenging, and chemotherapy drugs are prone to inducing drug resistance, resulting in a five-year survival rate of only 13.1%. Therefore, in-depth analysis of the occurrence, development, and drug resistance mechanisms of colon cancer is of great clinical significance for optimizing treatment strategies and improving patient prognosis. As one of the homologous recombination repair proteins, minichromosomal maintenance protein 8 (MCM8) not only participates in DNA replication initiation, homologous recombination repair, and genome stability maintenance in normal cells, but also has been reported to be abnormally highly expressed in multiple tumors (e.g. glioblastoma, cholangiocarcinoma, bladder cancer) to promote malignant progression. METHODS: This study focused on the expression and function of MCM8 in colon cancer. The expression level of MCM8 in colon cancer tissues and cells was detected, and its correlation with patients’ clinicopathological features and prognosis was analyzed. Combined with cell function experiments, protein-protein interaction verification assays, and in vivo tumorigenesis experiments, the effects of MCM8 on the biological behaviors of colon cancer cells and the underlying molecular mechanisms were explored. Meanwhile, rescue experiments were conducted to identify the key downstream molecules and pathways mediated by MCM8. Additionally, the relationship between MCM8 and chemoresistance of colon cancer cells was investigated. RESULTS: Our study indicated that MCM8 promotes the transition of the cell cycle from the G1 phase to the S phase in CRC cell lines(SW620, HCT116, CX-1). Moreover, our study showed that MCM8 interacted with Cdc42(Cell Division Cycle 42) and promoted its protein stability by competitively inhibiting the ubiquitination modification of Cdc42‘s E3 ubiquitin ligase HRD1(Hydroxymethylglutaryl Reductase Degradation Protein 1). The rescue experiment showed that MCM8 promoted the proliferation, cell cycle progression, invasion, tumor-forming ability in vivo and resistance to 5-FU of CRC cell lines (SW620FR, HCT15FR) through Cdc42, while inhibiting cell apoptosis. CONCLUSIONS: MCM8 is abnormally highly expressed in CRC and stabilizes Cdc42 protein by competitively inhibiting HRD1, thereby promoting the occurrence and development of CRC and the formation of 5-FU resistance.

Humans

Development of a cell-based nanoluciferase reporter system for high-throughput screening of HBV cccDNA inhibitors.

Hepatitis B virus (HBV) persistence is sustained by the viral covalently closed circular DNA (cccDNA) minichromosome, which remains a major barrier to curative antiviral therapies. The lack of reliable quantitative cccDNA detection methods and surrogate markers has hindered efforts to target cccDNA in antiviral high-throughput screening (HTS). Here, we established a novel inducible cccDNA-dependent nanoluciferase (NLuc) reporter cell line, designated HepBLE12, by inserting an in-frame 11-amino acid split-NLuc HiBiT tag into the precore (pC) coding region of an HBV transgene. The resulting 1.3-kDa HiBiT tag on pC serves as the detection module of the split NLuc system, generating quantitative luminescence upon high-affinity complementation with the cognate 18-kDa LgBiT subunit in cell lysates. Notably, the HiBiT assay enables direct detection of intracellular HiBiT-pC protein rather than secreted HBeAg, providing a reporter signal more closely linked to cccDNA activity. HepBLE12&#x202f;cells exhibited inducible and robust viral DNA replication, and the cccDNA-dependent HiBiT signal was validated under diverse experimental conditions that modulate cccDNA formation or transcription. We further miniaturized the assay to a 384-well format and optimized key parameters following standard HTS assay development practices. The assay was successfully automated and demonstrated excellent performance in a multi-day variability study and a pilot screen, with signal-to-background (S/B)&#x202f;&#x2248;&#x202f;9, coefficient of variance (CV)&#x202f;<&#x202f;10%, and average Z-factor value of 0.74, exceeding canonical HTS quality benchmarks. Together, the HepBLE12 cell-based HTS platform provides a robust and practical tool for identifying inhibitors targeting HBV cccDNA.

Hepatitis B virus